ReviewMicrobial cell factories2026
Engineered Escherichia coli as a microbial cell factory for intracellular protein delivery: strains, vectors, mechanisms, and therapeutic applications.
Review in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Escherichia coli (E. coli) has emerged as a promising vector of therapeutic proteins into target cells due to its high fidelity to genetic manipulations, short generation times, and well-known molecular pathways. Over the years, the use of E. coli as a delivery vector has been explored in various mechanisms. This review aims to discuss the mechanisms through which E. coli can express and transport therapeutic proteins to target cells. Various delivery systems have been developed using E. coli, starting from the simple plasmid vectors, to outer membrane vesicles and, in some cases, live bacteria itself which can transport proteins into cells. These E. coli based systems are of immense potential in targeted drug delivery and therapeutic applications and have made E. coli to lead in novel biotechnological developments. However, there are still many challenges, concerning the improvement of the safety and efficacy of E. coli for protein delivery into cells, especially in regards to delivery efficiency and directional control in a real biological environment. Most of these challenges have been solved by the recent developments in synthetic biology, genetic engineering and E. coli is gradually becoming a versatile vector for protein therapeutic delivery into cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.